Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Viral Vectors And Plasmid DNA Market Size And Revenue Forecast Through 2030
The viral vectors and plasmid DNA market has experienced notable expansion in recent years. Projections indicate an increase from $1.38 billion in 2025 to $1.47 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.2%. This historic growth has been driven by factors such as the constrained supply of viral vectors, a dependence on research-grade plasmid DNA, a rising number of gene therapy development programs, heightened research and development efforts within the biopharmaceutical sector, and the widespread use of established viral vector platforms.
The market for viral vectors and plasmid DNA is forecast to experience significant growth in the coming years, with projections indicating a rise to $1.89 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.6%. This expansion during the forecast period is driven by factors including the creation of clinical-grade and GMP-compliant plasmid DNA, the broadening of viral vector uses in oncology and infectious diseases, heightened investment in gene therapy, an increasing need for immunotherapeutic approaches, and the uptake of innovative vector systems like adeno-associated and lentiviral vectors. Key developments expected in this period encompass the growing utilization of plasmid DNA and viral vectors within gene therapy, the proliferation of viral vector platforms tailored for cancer and genetic disorder management, a surge in GMP-grade plasmid DNA output for clinical purposes, intensified investigation into novel adeno-associated and lentiviral vector technologies, and the incorporation of these elements into immunotherapy and vaccine development.
Download A Free Sample Report For Comprehensive Market Insights:
Viral Vectors And Plasmid DNA Market Development Factors: Which Trends Are Supporting Demand?
The viral vector and plasmid DNA market is expected to be driven forward by the rising number of tuberculosis cases. Tuberculosis (TB) is a contagious, severe infectious illness brought on by bacteria, mainly attacking the lungs but also capable of affecting other body parts. Plasmid DNA vaccines have been utilized to deliver genes coding for microbial antigens specific to TB. These vaccines can be tailored to express particular antigens from Mycobacterium tuberculosis, the pathogen responsible for the disease, and are typically given via intramuscular injection. For example, data from GOV.UK in February 2024, a UK government entity, revealed that TB cases in England climbed by 10.7% in 2023, increasing from 4,380 in 2022 to 4,850. Consequently, the growing TB incidence is fueling expansion in the viral vector and plasmid DNA market.
Viral Vectors And Plasmid DNA Market Segment Analysis And Revenue Opportunities
The viral vectors and plasmid dna market covered in this report is segmented –
1) By Product: Plasmid DNA, Viral Vectors
2) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases
3) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications
4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies
Subsegments:
1) By Plasmid DNA: Research-Grade Plasmid DNA, Clinical-Grade Plasmid DNA, GMP (Good Manufacturing Practice) Plasmid DNA
2) By Viral Vectors: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Vesicular Stomatitis Virus (VSV) Vectors
Viral Vectors And Plasmid DNA Market Transformation Trends: Which Innovations Are Driving Change?
Key players in the viral vectors and plasmid DNA market are increasingly focusing on developing innovative solutions, such as helper plasmids, to strengthen their competitive position. A helper plasmid represents a type of plasmid DNA used in producing viral vectors like adeno-associated viral vectors (AAV), commonly applied in gene therapy. For example, in March 2023, Charles River Laboratories International Inc., a US-based pharmaceutical firm, introduced its off-the-shelf pHelper helper plasmid, designed to accelerate processes from early discovery through commercial production of AAV-based gene therapy programs while ensuring supply security. As part of an expanding range of contract development and manufacturing organization (CDMO) offerings, these helper plasmids aim to protect viral vector packaging in cell and gene therapy operations and simplify complex supply chains. The production of adeno-associated viral vectors (AAV), frequently used in gene therapy, relies on helper plasmids to facilitate their creation.
Viral Vectors And Plasmid DNA Market Leading Players Shaping Industry Direction
Major companies operating in the viral vectors and plasmid dna market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, ??n?k? ??r??r?t??n, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, Creative Biogene
Access The Complete Viral Vectors And Plasmid DNA Market Report:
Viral Vectors And Plasmid DNA Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the viral vectors and plasmid DNA market in 2025. The Middle East is expected to be the fastest-growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid dna market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model